Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
The most effective method to Shake Hands Expertly: A Bit by bit Guide - 26 Useful Home Espresso Machines
- 3'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- 4One month of war on Iran cost Arab countries up to $194bn: UNDP
- 5NASA will bring space station crew home early after medical issue
- The most effective method to Involve Handshakes for Compromise and Compromise
- RFK Jr. says he's following 'gold standard' science. Here's what to know
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic
- Surprising links between autism, Alzheimer’s could change how we treat both
- The breakout star of NASA's Artemis 2 moon mission isn't an astronaut — it's the space toilet
- IDF says up to 90% of Iran’s weapons industry could be hit within days
- 6 Well known Ladies' Fragrances On the planet
- Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it
